Advertisement
UK markets close in 3 hours 7 minutes
  • FTSE 100

    8,145.27
    -18.40 (-0.23%)
     
  • FTSE 250

    20,120.46
    -75.49 (-0.37%)
     
  • AIM

    777.11
    -3.32 (-0.43%)
     
  • GBP/EUR

    1.1870
    -0.0009 (-0.07%)
     
  • GBP/USD

    1.2689
    -0.0072 (-0.56%)
     
  • Bitcoin GBP

    52,965.11
    -469.73 (-0.88%)
     
  • CMC Crypto 200

    1,426.72
    +8.84 (+0.63%)
     
  • S&P 500

    5,433.74
    +12.71 (+0.23%)
     
  • DOW

    38,647.10
    -65.11 (-0.17%)
     
  • CRUDE OIL

    78.83
    +0.21 (+0.27%)
     
  • GOLD FUTURES

    2,347.50
    +29.50 (+1.27%)
     
  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     
  • HANG SENG

    17,941.78
    -170.85 (-0.94%)
     
  • DAX

    18,020.83
    -244.85 (-1.34%)
     
  • CAC 40

    7,524.55
    -183.47 (-2.38%)
     

Arcus Biosciences First Quarter 2024 Earnings: Beats Expectations

Arcus Biosciences (NYSE:RCUS) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$145.0m (up 480% from 1Q 2023).

  • Net loss: US$4.00m (loss narrowed by 95% from 1Q 2023).

  • US$0.046 loss per share (improved from US$1.10 loss in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Arcus Biosciences Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 95%.

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's shares are up 4.2% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 3 warning signs for Arcus Biosciences you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.